Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2018 08:30 ET | Source: Amaranth Medical, Inc.

Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium

MOUNTAIN VIEW, CA , May 23, 2018 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, provided...
October 25, 2017 13:21 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Showcases Breadth of BRS Pipeline at TCT, Unveiling 9-mo Interim Imaging Results from 98 micron MAGNITUDE and Update on 115-micron APTITUDE

MOUNTAIN VIEW, CA , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, will...
November 01, 2016 08:00 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold

MOUNTAIN VIEW, CA , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation...
October 31, 2016 12:30 ET | Source: Amaranth Medical, Inc.

Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT

MOUNTAIN VIEW, CA, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that a presentation of the 9-month clinical and imaging results from the...
June 06, 2016 08:00 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold

MOUNTAIN VIEW, CA , June 06, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that it completed enrollment in May 2016 in the RENASCENT-II study of its...
May 18, 2016 03:01 ET | Source: Amaranth Medical, Inc.

Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold in May

MOUNTAIN VIEW, CA , May 18, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, provided a clinical update on its ongoing RENASCENT-II study of its novel APTITUDE™...
October 15, 2015 08:00 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold

MOUNTAIN VIEW, CA, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international...
May 18, 2015 15:12 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Reports Findings from Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015

Mountain View, CA, May 18, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced plans to report clinical results from the Company's ongoing trial of...
January 14, 2014 09:14 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Announces Investment from Boston Scientific

Mountain View, CA, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, today announced the closing of an equity investment by Boston Scientific Corporation...
October 28, 2013 08:00 ET | Source: Amaranth Medical, Inc.

Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE(TM) Bioresorbable Scaffold

MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its first-in-human study...